Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
NGL Fine-ChemNSE:NGLFINE -0.45%78 Return-on-Tangible-Asset is 9.90% as of Mar. 2026, which is 17% below its 10-year median of 11.89. GuruFocus rates NSE:NGLFINE with a GF Score™ of 78/100 and a GF Value™ of ₹2,852.38 (Modestly Overvalued). The stock has 8 warning signs investors should review. Among 1,008 Drug Manufacturers companies, NGL Fine-Chem ranks better than 77.58% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. NGL Fine-Chem's annualizedNet Income for the quarter that ended in Mar. 2026 was ₹539 Mil. NGL Fine-Chem's average total tangible assets for the quarter that ended in Mar. 2026 was ₹5,451 Mil. Therefore, NGL Fine-Chem's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2026 was 9.90%.
The historical rank and industry rank for NGL Fine-Chem's Return-on-Tangible-Asset or its related term are showing as below:
NSE:NGLFINE'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: 5.36 Med: 11.89 Max: 31.5
Current: 9.86
During the past 13 years, NGL Fine-Chem's highest Return-on-Tangible-Asset was 31.50%. The lowest was 5.36%. And the median was 11.89%.
NSE:NGLFINE's Return-on-Tangible-Asset is ranked better than 77.58% of 1008
companies
in the Drug Manufacturers industry
Industry Median: 3.12
vs NSE:NGLFINE: 9.86
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
NGL Fine-Chem Return-on-Tangible-Asset Related Terms
NGL Fine-Chem Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for NGL Fine-Chem's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:NGLFINE vs LLY, JNJ, ABBV: Return-on-Tangible-Asset Comparison
For the Drug Manufacturers - General subindustry, NGL Fine-Chem's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NGL Fine-Chem Return-on-Tangible-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, NGL Fine-Chem's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where NGL Fine-Chem's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
What does a Return-on-Tangible-Asset of 9.90% mean?
NGL Fine-Chem (NSE:NGLFINE) has a Return-on-Tangible-Asset of 9.90% as of Mar. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on NGL Fine-Chem and its competitors. This is 17% below median its historical median of 11.89. Over the past decade, NGL Fine-Chem's Return-on-Tangible-Asset has ranged from 5.36 to 31.50. According to the industry distribution chart, NGL Fine-Chem ranks #226 out of 1008 companies in the Drug Manufacturers industry, placing it in the top 22.4%.
Is NGL Fine-Chem's Return-on-Tangible-Asset too high?
NGL Fine-Chem's current Return-on-Tangible-Asset of 9.90% is 17% below median its 10-year median of 11.89. Over the past 10 years, this metric has ranged from a low of 5.36 to a high of 31.50. The Drug Manufacturers industry median Return-on-Tangible-Asset is 3.12. NGL Fine-Chem's value of 9.90% is 217.3% above this industry median. Based on the distribution chart, NGL Fine-Chem ranks #226 out of 1008 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, NGL Fine-Chem has a GF Score™ of 78/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does NGL Fine-Chem's Return-on-Tangible-Asset compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, NGL Fine-Chem ranks #226 out of 1008 companies for Return-on-Tangible-Asset. This places NGL Fine-Chem in the top 22% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Asset is 3.12. NGL Fine-Chem's value of 9.90% is 217.3% above this benchmark. Historically, NGL Fine-Chem's own Return-on-Tangible-Asset has ranged from 5.36 to 31.50 over the past decade. While the company's 10-year median is 11.89 vs. the industry median of 3.12, NGL Fine-Chem has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Drug Manufacturers company?
The median Return-on-Tangible-Asset among Drug Manufacturers companies is 3.12, based on 1,008 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. NGL Fine-Chem's current Return-on-Tangible-Asset of 9.90% is 217.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on NGL Fine-Chem and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Asset is 3.12 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. NGL Fine-Chem's current Return-on-Tangible-Asset is 9.90%, which is 17% below median its own 10-year median of 11.89. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NGL Fine-Chem stock overvalued right now?
Based on GuruFocus' analysis, NGL Fine-Chem (NSE:NGLFINE) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹2,852.38, compared to a current price of ₹3,212.00 — trading 12.6% above its estimated fair value. The current Return-on-Tangible-Asset is 9.90%, which is 17% below median its 10-year median of 11.89 and 217.3% above the Drug Manufacturers industry median of 3.12. NGL Fine-Chem's overall GF Score™ is 78/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For NGL Fine-Chem (NSE:NGLFINE), the current Return-on-Tangible-Asset is 9.90% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is NGL Fine-Chem (NSE:NGLFINE) Overvalued in 2026?
Based on GuruFocus' analysis, NGL Fine-Chem stock appears to be overvalued.
The current stock price of ₹3,212.00 is trading 12.6% above its estimated GF Value™ of ₹2,852.38.
GuruFocus considers NGL Fine-Chem to be Modestly Overvalued.
Key valuation signals for NSE:NGLFINE:
Return-on-Tangible-Asset: 9.90% (17% below median its 10-year median of 11.89)
GF Value™: ₹2,852.38 vs. price of ₹3,212.00 (12.6% above fair value)
Industry Position: 217.3% above the Drug Manufacturers median (#226 of 1008)
No single metric tells the full story. See the NSE:NGLFINE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
NGL Fine-Chem Ltd is an Indian company engaged in the pharmaceutical business. It is a manufacturer of pharmaceuticals and intermediates for use in veterinary and human health, catering to various companies to custom-manufacture pharmaceuticals. The company's product portfolio comprises animal health APIs such as homidium chloride, nitroxynil, clorsulon, decoquinate, fenbendazole, etc.; human health APIs such as nitazoxanide and atovaquone; drug intermediates and specialty chemicals; and finished dosage forms such as diminazene aceturate granules and homidium chloride tablets. Geographically, the group generates maximum revenue from the Asia-Pacific region, and the rest from India, Europe, the USA, and the rest of the world.
78GF Score
Get the complete analysis for NSE:NGLFINE
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:NGLFINE has been successfully added to your 
